{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:09:55Z","timestamp":1763554195524,"version":"3.45.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11096-025-02010-1","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T07:53:30Z","timestamp":1759132410000},"page":"1967-1978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacovigilance assessment of drug-induced aplastic anemia: analysis of the FDA adverse event reporting system"],"prefix":"10.1007","volume":"47","author":[{"given":"Fan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanmu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"1","key":"2010_CR1","doi-asserted-by":"publisher","first-page":"10528","DOI":"10.1038\/s41598-022-14665-1","volume":"12","author":"M He","year":"2022","unstructured":"He M, Gui R, Zu Y, et al. Successful outcomes of second hematopoietic stem cell transplantation for graft failure in pediatric patients with severe aplastic anemia. Sci Rep. 2022;12(1):10528.","journal-title":"Sci Rep"},{"key":"2010_CR2","doi-asserted-by":"publisher","first-page":"1442613","DOI":"10.1155\/2022\/1442613","volume":"2022","author":"U Zaidi","year":"2022","unstructured":"Zaidi U, Fatima M, Samad SA, et al. Fludarabine\/cyclophosphamide conditioning regimen in aplastic anemia patients receiving matched-sibling donor transplant is non-inferior to ATG\/cyclophosphamide: a single-center experience from Pakistan. Stem Cells Int. 2022;2022:1442613.","journal-title":"Stem Cells Int."},{"issue":"9","key":"2010_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.4103\/1947-2714.100980","volume":"4","author":"H Biswajit","year":"2012","unstructured":"Biswajit H, Pratim PP, Kumar ST, et al. Aplastic anemia: a common hematological abnormality among peripheral pancytopenia. N Am J Med Sci. 2012;4(9):384\u20138.","journal-title":"N Am J Med Sci"},{"key":"2010_CR4","doi-asserted-by":"publisher","first-page":"1064723","DOI":"10.3389\/fendo.2023.1064723","volume":"14","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Xia XY, Zhang W, et al. Clinical characteristics of antithyroid drug-induced aplastic anemia cases over the past 30 years. Front Endocrinol (Lausanne). 2023;14:1064723.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2010_CR5","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/healthcare10030420","volume":"10","author":"MA Khaleel","year":"2022","unstructured":"Khaleel MA, Khan AH, Ghadzi SMS, et al. A standardized dataset of a spontaneous adverse event reporting system. Healthcare. 2022;10:420. https:\/\/doi.org\/10.3390\/healthcare10030420.","journal-title":"Healthcare"},{"issue":"5","key":"2010_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.615","volume":"10","author":"EM Rodriguez","year":"2001","unstructured":"Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidem Drug Saf. 2001;10(5):407\u201310.","journal-title":"Pharmacoepidem Drug Saf"},{"issue":"1","key":"2010_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12882-023-03171-9","volume":"24","author":"P Chen","year":"2023","unstructured":"Chen P, Zhu J, Xu Y, et al. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database. BMC Nephrol. 2023;24(1):107.","journal-title":"BMC Nephrol"},{"key":"2010_CR8","doi-asserted-by":"publisher","first-page":"1057134","DOI":"10.3389\/fphar.2023.1057134","volume":"14","author":"Q Guo","year":"2023","unstructured":"Guo Q, Zhao JN, Liu T, et al. Immune checkpoint inhibitor-induced aplastic anaemia: case series and large-scale pharmacovigilance analysis. Front Pharmacol. 2023;14:1057134.","journal-title":"Front Pharmacol"},{"key":"2010_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2147\/TCRM.S325742","volume":"17","author":"MA Syed","year":"2021","unstructured":"Syed MA, Atta Ur Rahman A, Shah Syed MN, et al. The relationship of drug therapy to aplastic anemia in Pakistan: a hospital-based case control study. Ther Clin Risk Manag. 2021;17:903\u20138.","journal-title":"Ther Clin Risk Manag"},{"key":"2010_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1488725","volume":"15","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Khouri C, et al. The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline. Front Pharmacol. 2024;15:1488725.","journal-title":"Front Pharmacol"},{"key":"2010_CR11","doi-asserted-by":"publisher","first-page":"1485190","DOI":"10.3389\/fphar.2024.1485190","volume":"15","author":"Q Liu","year":"2024","unstructured":"Liu Q, Cui Z, Deng C, et al. A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases. Front Pharmacol. 2024;15:1485190.","journal-title":"Front Pharmacol"},{"issue":"10","key":"2010_CR12","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/jamia\/ocy077","volume":"25","author":"J Mower","year":"2018","unstructured":"Mower J, Subramanian D, Cohen T. Learning predictive models of drug side-effect relationships from distributed representations of literature-derived semantic predications. J Am Med Inform Assoc. 2018;25(10):1339\u201350.","journal-title":"J Am Med Inform Assoc"},{"key":"2010_CR13","doi-asserted-by":"publisher","first-page":"767999","DOI":"10.3389\/fphar.2021.767999","volume":"12","author":"S Bian","year":"2021","unstructured":"Bian S, Zhang P, Li L, et al. Anaphylaxis associated with allergen specific immunotherapy, omalizumab, and dupilumab: a real world study based on the us food and drug administration adverse event reporting system. Front Pharmacol. 2021;12:767999.","journal-title":"Front Pharmacol"},{"key":"2010_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.716648","volume":"9","author":"X Tang","year":"2021","unstructured":"Tang X, Xu X, Li J, et al. Cardiotoxicity in biological agent-targeted therapy for rheumatoid arthritis: ADR signal mining and analysis of food and drug administration adverse event reporting system database. Front Pediatr. 2021;9:716648.","journal-title":"Front Pediatr"},{"key":"2010_CR15","doi-asserted-by":"publisher","first-page":"1524159","DOI":"10.3389\/fphar.2025.1524159","volume":"16","author":"P Jia","year":"2025","unstructured":"Jia P, Zhou Y, Gao Y, et al. Real-world pharmacovigilance investigation of imipenem\/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database. Front Pharmacol. 2025;16:1524159.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2010_CR16","doi-asserted-by":"publisher","first-page":"9218","DOI":"10.1038\/s41598-025-92741-y","volume":"15","author":"F Liu","year":"2025","unstructured":"Liu F, Su H, Wei W. Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system. Sci Rep. 2025;15(1):9218.","journal-title":"Sci Rep"},{"issue":"6","key":"2010_CR17","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","volume":"91","author":"R Harpaz","year":"2012","unstructured":"Harpaz R, DuMouchel W, Shah NH, et al. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010\u201321.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2010_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf. 2002;25(6):381\u201392.","journal-title":"Drug Saf"},{"issue":"3","key":"2010_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53(3):177.","journal-title":"Am Stat"},{"key":"2010_CR20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2147\/NSS.S513538","volume":"17","author":"S Wei","year":"2025","unstructured":"Wei S, Song X, Chen R, et al. Exploring the top 50 drugs associated with restless legs syndrome based on the FDA data from 2004 to 2024. Nat Sci Sleep. 2025;17:929\u201346.","journal-title":"Nat Sci Sleep"},{"key":"2010_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2288-14-17","volume":"14","author":"F Leroy","year":"2014","unstructured":"Leroy F, Dauxois JY, Th\u00e9ophile H, et al. Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases. BMC Med Res Methodol. 2014;14:17.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2010_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12874-021-01450-3","volume":"21","author":"\u00c9 Courtois","year":"2021","unstructured":"Courtois \u00c9, Tubert-Bitter P, Ahmed I. New adaptive lasso approaches for variable selection in automated pharmacovigilance signal detection. BMC Med Res Methodol. 2021;21(1):271.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"2010_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1177\/0962280216643116","volume":"27","author":"I Ahmed","year":"2018","unstructured":"Ahmed I, Pariente A, Tubert-Bitter P. Class-imbalanced subsampling lasso algorithm for discovering adverse drug reactions. Stat Methods Med Res. 2018;27(3):785\u201397.","journal-title":"Stat Methods Med Res"},{"issue":"17","key":"2010_CR24","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643\u201356.","journal-title":"N Engl J Med"},{"key":"2010_CR25","doi-asserted-by":"publisher","first-page":"1378432","DOI":"10.3389\/fimmu.2024.1378432","volume":"15","author":"A Piekarska","year":"2024","unstructured":"Piekarska A, Pawelec K, Szmigielska-Kap\u0142on A, et al. The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults. Front Immunol. 2024;15:1378432.","journal-title":"Front Immunol"},{"issue":"9","key":"2010_CR26","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/j.1875-9114.2012.01108.x","volume":"32","author":"MP Pai","year":"2012","unstructured":"Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32(9):856\u201368.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2010_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40264-022-01258-0","volume":"46","author":"D Sartori","year":"2023","unstructured":"Sartori D, Aronson JK, Nor\u00e9n GN, et al. Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: a scoping review of the global literature. Drug Saf. 2023;46(2):109\u201320.","journal-title":"Drug Saf"},{"issue":"3","key":"2010_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","volume":"35","author":"ST Ngo","year":"2014","unstructured":"Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35(3):347\u201369.","journal-title":"Front Neuroendocrinol"},{"issue":"6","key":"2010_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1055\/a-2575-1530","volume":"75","author":"Q Xu","year":"2025","unstructured":"Xu Q, Cheng H, Sun X, et al. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for gender of voriconazole drugs. Drug Res (Stuttg). 2025;75(6):218\u201324.","journal-title":"Drug Res (Stuttg)"},{"issue":"3","key":"2010_CR30","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.19236","volume":"204","author":"A Kulasekararaj","year":"2024","unstructured":"Kulasekararaj A, Cavenagh J, Dokal I, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology guideline. Br J Haematol. 2024;204(3):784\u2013804.","journal-title":"Br J Haematol"},{"issue":"6","key":"2010_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/ejh.13153","volume":"101","author":"RM Shallis","year":"2018","unstructured":"Shallis RM, Ahmad R, Zeidan AM. Aplastic anemia: etiology, molecular pathogenesis, and emerging concepts. Eur J Haematol. 2018;101(6):711\u201320.","journal-title":"Eur J Haematol"},{"issue":"1","key":"2010_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/gm409","volume":"5","author":"AK Daly","year":"2013","unstructured":"Daly AK. Pharmacogenomics of adverse drug reactions. Genome Med. 2013;5(1):5.","journal-title":"Genome Med"},{"issue":"1","key":"2010_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2165\/00003495-198631010-00004","volume":"31","author":"PC Vincent","year":"1986","unstructured":"Vincent PC. Drug-induced aplastic anaemia and agranulocytosis. Incidence and mechanisms. Drugs. 1986;31(1):52\u201363.","journal-title":"Drugs"},{"issue":"1","key":"2010_CR34","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/s41598-020-58386-9","volume":"10","author":"EM Gottwald","year":"2020","unstructured":"Gottwald EM, Schuh CD, Dr\u00fccker P, et al. The iron chelator deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability. Sci Rep. 2020;10(1):1577.","journal-title":"Sci Rep"},{"issue":"1","key":"2010_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000506387","volume":"144","author":"J Tu","year":"2021","unstructured":"Tu J, Pan H, Li R, et al. PNH clones for aplastic anemia with immunosuppressive therapy: a systematic review and meta-analysis. Acta Haematol. 2021;144(1):34\u201343.","journal-title":"Acta Haematol"},{"key":"2010_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/975039","volume":"2010","author":"G Comez","year":"2010","unstructured":"Comez G, Sevinc A, Sever ON, et al. An unusual case of aplastic anemia caused by temozolomide. Case Rep Med. 2010;2010:975039. https:\/\/doi.org\/10.1155\/2010\/975039.","journal-title":"Case Rep Med"},{"issue":"9","key":"2010_CR37","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/SMJ.0b013e3181b1d2fa","volume":"102","author":"BJ George","year":"2009","unstructured":"George BJ, Eichinger JB, Richard TJ. A rare case of aplastic anemia caused by temozolomide. South Med J. 2009;102(9):974\u20136. https:\/\/doi.org\/10.1097\/SMJ.0b013e3181b1d2fa.","journal-title":"South Med J"},{"issue":"6","key":"2010_CR38","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/neuonc\/noab240","volume":"24","author":"AK Park","year":"2022","unstructured":"Park AK, Waheed A, Forst DA, et al. Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies. Neuro Oncol. 2022;24(6):964\u201373. https:\/\/doi.org\/10.1093\/neuonc\/noab240.","journal-title":"Neuro Oncol"},{"issue":"1","key":"2010_CR39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1515\/jbcr-2015-0128","volume":"7","author":"MG Ganeva","year":"2015","unstructured":"Ganeva MG, Gancheva TT, Baldaranov ID, et al. Risks of oral methotrexate administration in outpatients. J Biomed Clin Res. 2015;7(1):59\u201364.","journal-title":"J Biomed Clin Res"},{"issue":"2","key":"2010_CR40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4103\/0972-4958.121605","volume":"27","author":"FK Jebasingh","year":"2013","unstructured":"Jebasingh FK, Prasad L, Laishram RS, et al. Early onset pancytopenia in patient on methotrexate. J Med Soc. 2013;27(2):156\u20138.","journal-title":"J Med Soc"},{"issue":"4","key":"2010_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/pra.0000000000000641","volume":"28","author":"J Bade-Boon","year":"2022","unstructured":"Bade-Boon J, Dobson H, Breadon C. A fatal case of factitious aplastic anemia. J Psychiatr Pract. 2022;28(4):339\u201343. https:\/\/doi.org\/10.1097\/pra.0000000000000641.","journal-title":"J Psychiatr Pract"},{"issue":"8","key":"2010_CR42","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1182\/blood.2021012775","volume":"139","author":"P Blombery","year":"2022","unstructured":"Blombery P, Lew TE, Dengler MA, et al. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood. 2022;139(8):1198\u2013207. https:\/\/doi.org\/10.1182\/blood.2021012775.","journal-title":"Blood"},{"issue":"1","key":"2010_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1078155217726159","volume":"25","author":"RR Comito","year":"2019","unstructured":"Comito RR, Badu LA, Forcello N. Nivolumab-induced aplastic anemia: a case report and literature review. J Oncol Pharm Pract. 2019;25(1):221\u20135. https:\/\/doi.org\/10.1177\/1078155217726159.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"2010_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000495980","volume":"12","author":"K Rouvinov","year":"2019","unstructured":"Rouvinov K, Nalbandyan K, Kozlov V, et al. Nivolumab induced lethal aplastic anemia in a patient with metastatic melanoma. Case Rep Oncol. 2019;12(1):29\u201332. https:\/\/doi.org\/10.1159\/000495980.","journal-title":"Case Rep Oncol"},{"key":"2010_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40164-018-0098-5","volume":"7","author":"DE Meyers","year":"2018","unstructured":"Meyers DE, Hill WF, Suo A, et al. Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report. Exp Hematol Oncol. 2018;7:6. https:\/\/doi.org\/10.1186\/s40164-018-0098-5.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"2010_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100686","volume":"45","author":"S Goda","year":"2021","unstructured":"Goda S, Tsuji T, Matsumoto Y, et al. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab. Curr Probl Cancer. 2021;45(3):100686. https:\/\/doi.org\/10.1016\/j.currproblcancer.2020.100686.","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"2010_CR47","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/cmr.0000000000000724","volume":"31","author":"M Meri-Abad","year":"2021","unstructured":"Meri-Abad M, Cunquero Tom\u00e1s AJ, Jaime AB. Unexpected pure red series aplastic anemia secondary to pembrolizumab treatment: a case report and literature review. Melanoma Res. 2021;31(2):186\u20139. https:\/\/doi.org\/10.1097\/cmr.0000000000000724.","journal-title":"Melanoma Res"},{"issue":"4","key":"2010_CR48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4021\/wjon234w","volume":"1","author":"S Dacha","year":"2010","unstructured":"Dacha S, Reddivari AK, Latta S, et al. Carboplatin induced fatal autoimmune hemolytic anemia: first reported case. World J Oncol. 2010;1(4):173\u20135. https:\/\/doi.org\/10.4021\/wjon234w.","journal-title":"World J Oncol"},{"issue":"8","key":"2010_CR49","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1182\/bloodadvances.2020001726","volume":"4","author":"M Chan","year":"2020","unstructured":"Chan M, Silverstein WK, Nikonova A, et al. Bendamustine-induced immune hemolytic anemia: a case report and systematic review of the literature. Blood Adv. 2020;4(8):1756\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2020001726.","journal-title":"Blood Adv"},{"issue":"11","key":"2010_CR50","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1345\/aph.1M329","volume":"43","author":"LE Glance","year":"2009","unstructured":"Glance LE, Cumpston A, Kanate A, et al. Bendamustine-associated hemolytic anemia. Ann Pharmacother. 2009;43(11):1903\u20136. https:\/\/doi.org\/10.1345\/aph.1M329.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2010_CR51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1532\/ijh97.07027","volume":"86","author":"M Yamamoto","year":"2007","unstructured":"Yamamoto M, Suzuki N, Hatakeyama N, et al. Carbamazepine-induced hemolytic and aplastic crises associated with reduced glutathione peroxidase activity of erythrocytes. Int J Hematol. 2007;86(4):325\u20138. https:\/\/doi.org\/10.1532\/ijh97.07027.","journal-title":"Int J Hematol"},{"issue":"Nov","key":"2010_CR52","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/imj.14630","volume":"49","author":"FJ Fern\u00e1ndez-Fern\u00e1ndez","year":"2019","unstructured":"Fern\u00e1ndez-Fern\u00e1ndez FJ, Ameneiros-Lago E, Maceira-Quint\u00e1s C. Aplastic anaemia following carbamazepine-induced drug reaction with eosinophilia and systemic symptoms syndrome. Intern Med J. 2019;49(Nov):1456\u20138. https:\/\/doi.org\/10.1111\/imj.14630.","journal-title":"Intern Med J"},{"issue":"1","key":"2010_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40801-024-00462-x","volume":"12","author":"A Mansoor","year":"2025","unstructured":"Mansoor A, Shahzad M, Zulfiqar E, et al. Investigating the relationship between anti-seizure medications and bleeding disorders: a comprehensive review of the current literature. Drugs Real World Outcomes. 2025;12(1):1\u201315.","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"2010_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1684\/j.1950-6945.2005.tb00097.x","volume":"7","author":"AU Ural","year":"2005","unstructured":"Ural AU, Avcu F, Gokcil Z, et al. Leucopenia and thrombocytopenia possibly associated with lamotrigine use in a patient. Epileptic Disord. 2005;7(1):33\u20135.","journal-title":"Epileptic Disord"},{"issue":"2","key":"2010_CR55","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5414\/cnp71203","volume":"71","author":"YW Kim","year":"2009","unstructured":"Kim YW, Park BS, Ryu CH, et al. Allopurinol-induced aplastic anemia in a patient with chronic kidney disease. Clin Nephrol. 2009;71(2):203\u20136. https:\/\/doi.org\/10.5414\/cnp71203.","journal-title":"Clin Nephrol"},{"issue":"4","key":"2010_CR56","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1399-3062.2012.00728.x","volume":"14","author":"F Waki","year":"2012","unstructured":"Waki F, Ohnishi H, Shintani T, et al. Linezolid-induced pure red cell aplasia in a patient with Staphylococcus epidermidis infection after allogeneic stem cell transplantation. Transpl Infect Dis. 2012;14(4):E1-6. https:\/\/doi.org\/10.1111\/j.1399-3062.2012.00728.x.","journal-title":"Transpl Infect Dis"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02010-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:07:48Z","timestamp":1763554068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02010-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2010"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02010-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study utilized publicly available de-identified data from FAERS. Since no patient-identifiable information was accessed, institutional ethics approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}